Clinic of Internal Medicine, Asthma and Allergy
Lodz, 90-153, Poland
NCT Number: NCT01552161
The purpose of this study is to estimate the prevalence of allergic diseases and atopy among patients with angiographically confirmed coronary artery disease as well as to assess levels of serum allergic inflammation markers in this population.
Looking for future studies?
Notify Me30 year and older
All sexes
Observational
Lodz, 90-153, Poland
Cardiovascular disease (CVD) is one of the leading causes of death, disability and medical resources use worldwide. Atherosclerosis remains the basic pathology found in CVD. Based on theoretical knowledge and animal experimental models it can be hypothesized that allergic inflammation affects atherosclerotic plaque formation/disruption. The exact nature of such interaction remains unknown.
The process most probably takes place at the molecular level and involves both: specific interleukin formation and mast cells recruitment. On the one hand some pro-allergic interleukins have been found to inhibit atherosclerotic plaque formation in experimental animal models. However, other hypothesis conclude that mediators released by mast cells might encourage hypoxemia of the heart muscle cells and thus promote their necrosis. Mast cells and eosinophils -typically associated with allergy - are both found in human heart muscle, cross sections of coronary arteries and atherosclerotic plaques.
Atopic patients who are prone to IgE-mediated mast cell activation seem to run a lower risk of sudden cardiac death after myocardial infarction. It may be associated with the fact that atopy produces a mild haemostatic imbalance similar to that typical of aspirin - moderately long bleeding time, depressed platelet aggregability and delayed generation of thrombin in clotting blood. Tryptase, one of the mediators released from mast cells widely used marker of anaphylaxis, has recently been shown to be increased in sera of patients with angiographically significant narrowings in coronary arteries. These results are in accordance with the previous finding of increased total IgE (antibody involved in type I allergic reaction) post myocardial infarction. Allergic myocardial infarction (also known as Kounis syndrome) - a condition in which heart muscle ischemia results from allergic insult sometimes even in the absence of permanent coronary artery lesions - is another hint supporting the hypothesis of possible interaction between allergy and cardiovascular diseases.
Despite relatively many reports studying the association at molecular, in vitro and clinical level, the research investigating the problem as a whole, connecting laboratory data with clinical picture, is scarce. Our research aims at providing epidemiological evidence on the prevalence of allergy and atopy as well as serum allergy markers profile in subjects with coronary artery disease.
Our study is dedicated to post-coronary angiography subjects willing to express informed consent for study participation.
Coronarography has been chosen as a verification tool for several reasons:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Within a month from study recruitment completion.
Asthma, allergic rhinitis, allergic concjunctivitis, atopic dermatitis, contact eczema, drug, food and insect venom allergy will be assessed through a structured questionnaire based on ISAAC and ECRHS questions regarding allergy symptoms.
Additionally:
Asthma diagnosis is verified through basic spirometry, reversibility test, skin prick tests and/or serum specific IgE.
Allergic rhinitis diagnosis is verified through skin prick tests and/or serum specific IgE.
Time frame: Within a month from study recruitment completion.
Systemic tryptase will be measured with ImmunoCAP fluorescence enzyme immunoassay in patients sera.
Time frame: Within a month from study recruitment completion.
Systemic eosinophil cationic protein (ECP) will be measured with ImmunoCAP fluorescence enzyme immunoassay in patients sera.
Time frame: Within a month from study recruitment completion.
Atopy is defined as increased serum total/specific IgE and/or positive skin prick tests in the absence of relevant allergy clinical symptoms.
Medical University of Lodz
Other
Prevalence of Allergic Diseases and Atopy in Patients With Angiographically Confirmed Coronary Artery Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02596087
Actinomycetales Infections, Anemia
Boston, Massachusetts, United States
View Trial DetailsNCT01725815
Arterial Occlusive Diseases, Arteriosclerosis
Atlanta, Georgia, United States
View Trial DetailsNCT01050465
Acne Vulgaris, Acneiform Eruptions
View Trial DetailsNCT01039324
Arterial Occlusive Diseases, Arteriosclerosis
Durham, North Carolina, United States
View Trial Details